{"filing":{"accession_number":"0001648257-26-000066","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"hcm-20261021x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000066/hcm-20261021x6k.htm"},"events":[{"id":36550,"run_id":33699,"accession_number":"0001648257-26-000066","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This press release announces the closing of an exclusive development and license agreement between HUTCHMED and GSK for worldwide rights (excluding Greater China) to develop and commercialize HMPL-A830, a KRAS-EGFR antibody conjugate therapy. The agreement includes an upfront payment of US$110 million and potential milestone payments up to US$1.185 billion plus royalties, representing a material disposition of intellectual property rights and a significant financial transaction that would affect a reasonable investor's assessment of the company's value and strategic direction.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41004,"accession_number":"0001648257-26-000066","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This press release announces the closing of an exclusive development and license agreement between HUTCHMED and GSK for worldwide rights (excluding Greater China) to develop and commercialize HMPL-A830, a KRAS-EGFR antibody conjugate therapy. The agreement includes an upfront payment of US$110 million and potential milestone payments up to US$1.185 billion plus royalties, representing a material disposition of intellectual property rights and a significant financial transaction that would affect a reasonable investor's assessment of the company's value and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:09:41.064668+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41004,"accession_number":"0001648257-26-000066","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This press release announces the closing of an exclusive development and license agreement between HUTCHMED and GSK for worldwide rights (excluding Greater China) to develop and commercialize HMPL-A830, a KRAS-EGFR antibody conjugate therapy. The agreement includes an upfront payment of US$110 million and potential milestone payments up to US$1.185 billion plus royalties, representing a material disposition of intellectual property rights and a significant financial transaction that would affect a reasonable investor's assessment of the company's value and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:09:41.064668+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-10-21"}]}